<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29456690</article-id><article-id pub-id-type="pmc">5795603</article-id><article-id pub-id-type="doi">10.3892/etm.2018.5750</article-id><article-id pub-id-type="publisher-id">ETM-0-0-5750</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Protective effects of recombinant human brain natriuretic peptide in perioperative period during open heart surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yunbin</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5750"/><xref rid="c1-etm-0-0-5750" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5750"/></contrib><contrib contrib-type="author"><name><surname>Bao</surname><given-names>Weiguo</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5750"/></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Shi</given-names></name><xref ref-type="aff" rid="af1-etm-0-0-5750"/></contrib></contrib-group><aff id="af1-etm-0-0-5750">Department of Cardiovascular Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China</aff><author-notes><corresp id="c1-etm-0-0-5750"><italic>Correspondence to</italic>: Dr Yunbin Xu, Department of Cardiovascular Surgery, The Second Hospital of Shandong University, 247 Beiyuan Road, Tianqiao, Jinan, Shandong 250033, P.R. China, E-mail: <email>c8499931dileixu@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>1</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>15</volume><issue>3</issue><fpage>2869</fpage><lpage>2873</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Xu et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the present study was to evaluate the protective effects and safety aspects of recombinant human brain natriuretic peptide (rhBNP) on cardiac functions of patients undergoing open-heart surgery during perioperative period. In total, 150 patients undergoing open heart surgery in the Second Hospital of Shandong Universty from August 2015 to July 2016 were randomly divided into control group and observation group each with 75 cases. Patients in control group were treated by routine rehabilitation while patients in the observation group were treated by both the routine rehabilitation and rhBNP. All the observations were made before operation, after operation and 7 days after operation. The changes of N-terminal pro-brain natriuretic peptide (NT-proBNP) of patients, the left ventricular ejection fraction (LVEF), cardiac function [Cardiac output (CO), pulmonary capillary wedge pressure (PAWP) and central venous pressure (CVP)] of patients were measured. Further, respirator support time, ICU stay time, incidence of complications and vital signs (BP, HR, SaO2) of patients in the two groups were also compared. NT-proBNP levels of all patients improved after operation but it decreased in both groups after 7 days of operation. The decrease of NT-proBNP levels in observation group was significantly higher than that of control group. Whereas, LVEF, CO, PAWP and CVP of patients in both the groups increased after operation but effects were significantly higher in the observation group after 7 days of medication. Respirator support time and ICU stay time of patients in observation group were significantly shorter than those in control group, and the incidence of postoperative complications of patients in the observation group were significantly lower than the control group. Moreover, BP, HR and SaO2 of patients in observation group were significantly elevated in comparison to control group (P&#x0003c;0.05). Recombinant human brain natriuretic peptide (rhBNP) could significantly improve the cardiac functions of patients after open heart surgery, and is safe as well as reliable.</p></abstract><kwd-group><kwd>recombinant human brain natriuretic peptide</kwd><kwd>open heart surgery</kwd><kwd>perioperative period</kwd><kwd>cardiac function</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The rapid development of economy and the improvement of people's living standards allow more patients to accept heart surgery for the improvement of quality of life including the heart valve repair or replacement, cardiac surgery and coronary artery bypass grafting (<xref rid="b1-etm-0-0-5750" ref-type="bibr">1</xref>). The preoperative cardiac reserve functions of patients before the heart surgery are usually poor. Further, the surgical trauma, intraoperative myocardial ischemia and CPB are also prone to myocardial ischemia as well as ischemia reperfusion injury leading to low cardiac output syndrome (<xref rid="b2-etm-0-0-5750" ref-type="bibr">2</xref>,<xref rid="b3-etm-0-0-5750" ref-type="bibr">3</xref>). Therefore, it is very important to strengthen the protection of cardiac functions and prevention of the myocardial damage in patients undergoing cardiac surgery. This process would play an important role in improving the success rates of surgery and prognosis (<xref rid="b4-etm-0-0-5750" ref-type="bibr">4</xref>). Brain natriuretic peptide is a member of natriuretic peptide family. Recombinant human brain natriuretic peptide (rhBNP) is a kind of medicine for the treatment of heart failure, and is a recommended drug for acute as well as chronic heart failure (<xref rid="b5-etm-0-0-5750" ref-type="bibr">5</xref>). The related research showed that rhBNP has the ability to maintain the normal cardiac output, dilation of the pulmonary circulation/coronary circulation, reduction in cardiac load, protection of ischemic myocardium (<xref rid="b5-etm-0-0-5750" ref-type="bibr">5</xref>). Moreover, it could also achieve good clinical effects on heart functions after cardiac surgery (<xref rid="b5-etm-0-0-5750" ref-type="bibr">5</xref>). In the present study, patients were treated with the combination of routine treatment with recombinant human brain natriuretic peptide (rhBNP) after open-heart surgery and the clinical potential of this combination was evaluated.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>General information</title><p>One hundred and fifty patients undergoing open heart surgery in the Second Hospital of Shandong Universty from August 2015 to July 2016 were randomly divided into control group and observation group by computer, with 75 cases in each group. Patients in control group were treated by routine rehabilitation; patients in the observation group were treated by routine rehabilitation and rhBNP. Inclusion criteria: i) heart function grade II&#x02013;III of American New York Heart Association; ii) cardiopulmonary bypass support for cardiac surgery includes: valve repair or replacement, correction of congenital heart disease, coronary artery and major blood vessel related surgery; and iii) signed informed consent. Exclusion criteria: i) patients with cardiac shock and hypotension (SBP &#x0003c;90 mmHg); ii) severe renal insufficiency; and iii) allergy to the study drug and lactating women. There was no significant difference between the two groups of patients in general information (P&#x0003e;0.05), comparability is shown in <xref rid="tI-etm-0-0-5750" ref-type="table">Table I</xref>. The study was approved by the Ethics Committee of the Second Hospital of Shandong Universty and informed consents were signed by the patients and/or guardians.</p></sec><sec><title>Surgical methods</title><p>All patients underwent cardiac surgery with cardiopulmonary bypass support including: valve repair or replacement, repair of congenital heart disease, coronary artery and major blood vessel related surgery. Postoperative patients with tracheal intubation were sent to ICU to monitor the treatment along with maintenance of circulation and smooth respiration. Further, the late extubation extra corporeal circulation machine (German Stockert-sc type) and membrane oxygen device were used in the two groups of patients for the purpose of cardiopulmonary bypass. Compounds sodium chloride (900 ml), dexamethasone (10 mg), mannitol (250 ml) were used as the pre flushing fluids. Natriuretic peptide (Chengdu Nuodikang Biological Pharmaceutical Co. Ltd.: license number: NMPN S20050033) was added in observation group. Usage and dosage: Patients began to use the above dose regime within 24 h after surgery with continuous use of 24&#x02013;48 h. The recommended medication time was more than 48 h.</p></sec><sec><title>Evaluation criterion</title><p>Venous blood 4 ml of patients was collected before operation, after operation and 7 days after the operation. The N-terminal pro-brain natriuretic peptide (NT-proBNP) of patients were detected by automatic chemiluminescence immunoassay. The left ventricular ejection fraction (LVEF) was measured by color Doppler echocardiography before operation, after operation and 7 days after the operation. Cardiac function [cardiac output (CO), pulmonary capillary wedge pressure (PAWP), central venous pressure (CVP)] of patients were recorded and observed before the operation, after the operation and 7 days after the operation. The ventilator support time and ICU retention time of two groups of patients were recorded. The incidence rate of postoperative complications was observed. Blood pressure (BP), heart rate (HR) and blood oxygen saturation (SaO2) were monitored and observed after 7 days of treatment.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19.0 (SPSS Inc., Chicago, IL, USA) software was used for data processing. Measurement data are expressed by mean &#x000b1; SD, with t-test; count data were expressed by ratio with &#x003c7;<sup>2</sup> test, and P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>T-proBNP levels of all patients improved after operation</title><p>NT-proBNP levels of patients in both groups decreased 7 days after operation, and the decrease of NT-proBNP level in observation group was significantly higher than control group (P&#x0003c;0.05) (<xref rid="tII-etm-0-0-5750" ref-type="table">Table II</xref>).</p></sec><sec><title>The LVEF of patients in the groups increased after operation</title><p>LVEF of patients in observation group was significantly higher than that in control group after 7 days of medication (P&#x0003c;0.05). (<xref rid="tIII-etm-0-0-5750" ref-type="table">Table III</xref>).</p></sec><sec><title>Comparison of the heart function indexes of two groups</title><p>The indexes of CO, PAWP and CVP were significantly improved in the two groups compared with before operation, and the improvement degree of the observation group was better than that of the control group 7 days after medication (P&#x0003c;0.05) (<xref rid="f1-etm-0-0-5750" ref-type="fig">Figs. 1</xref>&#x02013;<xref rid="f3-etm-0-0-5750" ref-type="fig">3</xref>).</p></sec><sec><title>Mechanical ventilation time, ICU indwelling time and postoperative complications of two groups of patients</title><p>Compared with the control group, mechanical ventilation time and ICU indwelling time in the observation group were significantly shorter than those in the control group. Further, the incidence of postoperative complications was significantly lower than that of the control group, and the differences were statistically significant (<xref rid="tIV-etm-0-0-5750" ref-type="table">Table IV</xref>).</p></sec><sec><title>Comparison of vital signs in two groups of patients during perioperative period</title><p>SBP, DBP, HR, and SaO2 indexes of the observation group were significantly better than those of the control group (P&#x0003c;0.05) (<xref rid="tV-etm-0-0-5750" ref-type="table">Table V</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Cardiac reserve function is often affected after heart surgery due to surgical trauma and myocardial ischemia. Moreover, these patients are prone to myocardial ischemia and ischemia reperfusion injury that in turn leads to a variety of complications like heart failure, endotoxemia, the systemic inflammatory response syndrome and low cardiac output syndromes (<xref rid="b6-etm-0-0-5750" ref-type="bibr">6</xref>,<xref rid="b7-etm-0-0-5750" ref-type="bibr">7</xref>). The low cardiac output syndrome is the most severe complication with high mortality, and there are many factors of incidence, such as poor preoperative cardiac function in patients, myocardial ischemia time, poor cardiac malformation correction, intracardiac operation time, aortic clamping time, postoperative blood volume insufficiency, arrhythmia, cardiac tamponade and pulmonary artery hypertension (<xref rid="b8-etm-0-0-5750" ref-type="bibr">8</xref>). The reduction of the myocardial damage post-cardiac surgery and the protection of heart function have become the focus of clinical attention. Moreover, they have a profound impact on the success rate of surgery and prognosis of patients (<xref rid="b9-etm-0-0-5750" ref-type="bibr">9</xref>).</p><p>The secretion of NT-proBNP in patients with heart disease is closely related to the ventricular pressure load and volume load. When the ventricular wall tension load in patients increases, the NT-proBNP level would rise sharply. Moreover, the monitoring of it could prevent postoperative complications (<xref rid="b10-etm-0-0-5750" ref-type="bibr">10</xref>,<xref rid="b11-etm-0-0-5750" ref-type="bibr">11</xref>). Moreover, the plasma NT-proBNP levels of patients would continue to rise after open-heart surgery (<xref rid="b12-etm-0-0-5750" ref-type="bibr">12</xref>). The results of the present study showed that the NT-proBNP of patients of both groups increased after operation, which might be affected by anesthesia, surgical trauma, hemodynamic abnormalities, inflammatory stimulation, CPB, myocardial damage and decreased contractile ability. However, the levels of NT-proBNP in the two groups began to decrease after 7 days of treatment. This was the result after drug treatment that included inflammatory reaction of patients (<xref rid="b13-etm-0-0-5750" ref-type="bibr">13</xref>).</p><p>The postoperative CO, PAWP and CVP indicators of the two groups of patients were significantly improved and the observation group was significantly better than the control group after 7 days of treatment (P&#x0003c;0.05). The above observation could be justified in the light of the fact that the natriuretic peptide has balanced expansion arteriovenous/coronary artery diastolic function (<xref rid="b14-etm-0-0-5750" ref-type="bibr">14</xref>). A related study also showed improvements in the hemodynamic parameters after 15 min of treatment (<xref rid="b15-etm-0-0-5750" ref-type="bibr">15</xref>). The natriuretic peptide could improve the heart rate through the comprehensive effect (<xref rid="b16-etm-0-0-5750" ref-type="bibr">16</xref>). The results of this study showed that postoperative LVEF were higher than preoperative in the two groups of patients, and the observation group was significantly higher than the control group after 7 days of treatment (P&#x0003c;0.05). Moreover, natriuretic peptide has ability to directly affect myocardial cells, thereby reducing myocardial oxygen consumption, with inhibition of excessive stress reaction of the circulatory system, so as to have a protective effect on the heart (<xref rid="b17-etm-0-0-5750" ref-type="bibr">17</xref>,<xref rid="b18-etm-0-0-5750" ref-type="bibr">18</xref>).</p><p>In the present study, SBP, DBP, HR, and SaO2 indexes of the observation group were significantly better than those of the control group (P&#x0003c;0.05). This is due to the natriuretic peptide that has positive chronotropic effect, which not only caused reflex tachycardia, but also inhibited cardiac sympathetic nerve activity, thereby adjusted the blood pressure (<xref rid="b19-etm-0-0-5750" ref-type="bibr">19</xref>). Moreover, ICU indwelling time and ventilator support were also reduced via natriuretic peptide treatment. In summary, recombinant human brain natriuretic peptide (rhBNP) could protect the cardiac functions of patients after open-heart surgery, and it is safe and reliable. However, for the concrete conclusions, the study needs further exploration in future as the sample size and time were limited in the present study.</p></sec></body><back><ref-list><title>References</title><ref id="b1-etm-0-0-5750"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontoni</surname><given-names>G</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Gabbieri</surname><given-names>D</given-names></name><name><surname>Pedulli</surname><given-names>M</given-names></name><name><surname>Gambetti</surname><given-names>D</given-names></name><name><surname>Ghidoni</surname><given-names>I</given-names></name><name><surname>Rigatelli</surname><given-names>M</given-names></name></person-group><article-title>FC28-04 - Quality of life assessment after cardiac surgery in octogenarians: Is it really feasible?</article-title><source>Eur Psychiatry</source><volume>26</volume><fpage>1974</fpage><year>2011</year><uri xlink:type="simple" xlink:href="http://www.em-consulte.com/article/289736/fc28-04-quality-of-life-assessment-after-cardiac-s">http://www.em-consulte.com/article/289736/fc28-04-quality-of-life-assessment-after-cardiac-s</uri><pub-id pub-id-type="doi">10.1016/S0924-9338(11)72086-7</pub-id></element-citation></ref><ref id="b2-etm-0-0-5750"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mass&#x000e9;</surname><given-names>L</given-names></name><name><surname>Antonacci</surname><given-names>M</given-names></name></person-group><article-title>Low cardiac output syndrome: Identification and management</article-title><source>Crit Care Nurs Clin North Am</source><volume>17</volume><fpage>375</fpage><lpage>383</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.ccell.2005.07.005</pub-id><pub-id pub-id-type="pmid">16344207</pub-id></element-citation></ref><ref id="b3-etm-0-0-5750"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Algarni</surname><given-names>KD</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Yau</surname><given-names>TM</given-names></name></person-group><article-title>Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: Trends over 20 years</article-title><source>Ann Thorac Surg</source><volume>92</volume><fpage>1678</fpage><lpage>1684</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.athoracsur.2011.06.017</pub-id><pub-id pub-id-type="pmid">21939957</pub-id></element-citation></ref><ref id="b4-etm-0-0-5750"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangano</surname><given-names>DT</given-names></name><name><surname>Hollenberg</surname><given-names>M</given-names></name><name><surname>Fegert</surname><given-names>G</given-names></name><name><surname>Meyer</surname><given-names>ML</given-names></name><name><surname>London</surname><given-names>MJ</given-names></name><name><surname>Tubau</surname><given-names>JF</given-names></name><name><surname>Krupski</surname><given-names>WC</given-names></name></person-group><article-title>The Study of Perioperative Ischemia (SPI) Research Group: Perioperative myocardial ischemia in patients undergoing noncardiac surgery - I: Incidence and severity during the 4 day perioperative period</article-title><source>J Am Coll Cardiol</source><volume>17</volume><fpage>843</fpage><lpage>850</lpage><year>1991</year><pub-id pub-id-type="doi">10.1016/0735-1097(91)90864-6</pub-id><pub-id pub-id-type="pmid">1999618</pub-id></element-citation></ref><ref id="b5-etm-0-0-5750"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>XM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>JB</given-names></name><name><surname>Feng</surname><given-names>XX</given-names></name><name><surname>Zhang</surname><given-names>YB</given-names></name><name><surname>Chen</surname><given-names>QJ</given-names></name><name><surname>Ji</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>TS</given-names></name></person-group><article-title>Effects of rhBNP after PCI on non-invasivehemodynamic in acute myocardial infarction patients with left heart failure</article-title><source>Asian Pac J Trop Med</source><volume>9</volume><fpage>791</fpage><lpage>795</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.apjtm.2016.06.006</pub-id><pub-id pub-id-type="pmid">27569890</pub-id></element-citation></ref><ref id="b6-etm-0-0-5750"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targo&#x00144;ska</surname><given-names>S</given-names></name><name><surname>Kozio&#x00142;</surname><given-names>MM</given-names></name><name><surname>Czajkowski</surname><given-names>M</given-names></name><name><surname>St&#x00105;&#x0017c;ka</surname><given-names>J</given-names></name><name><surname>Kozio&#x00142;-Montewka</surname><given-names>M</given-names></name></person-group><article-title>Sternal wound complications after cardiac surgery - a case report</article-title><source>Wiad Lek</source><volume>68</volume><fpage>95</fpage><lpage>98</lpage><year>2015</year><comment>(In Polish)</comment><pub-id pub-id-type="pmid">26094341</pub-id></element-citation></ref><ref id="b7-etm-0-0-5750"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerneis</surname><given-names>CK</given-names></name><name><surname>Lafarge</surname><given-names>AL</given-names></name><name><surname>Larnier</surname><given-names>LL</given-names></name><name><surname>Scalbert</surname><given-names>F</given-names></name><name><surname>Brusset</surname><given-names>AB</given-names></name><name><surname>Estagnasie</surname><given-names>PE</given-names></name><name><surname>Squara</surname><given-names>PS</given-names></name></person-group><article-title>Bowel and related complications after cardiac surgery</article-title><source>Crit Care</source><volume>19</volume><issue>Suppl 1</issue><fpage>P375</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/cc14455</pub-id></element-citation></ref><ref id="b8-etm-0-0-5750"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>NJ</given-names></name><name><surname>Ashrafian</surname><given-names>H</given-names></name><name><surname>Drury</surname><given-names>NE</given-names></name><name><surname>Ranasinghe</surname><given-names>AM</given-names></name><name><surname>Contractor</surname><given-names>H</given-names></name><name><surname>Isackson</surname><given-names>H</given-names></name><name><surname>Calvert</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>LK</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Quinn</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: Results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial</article-title><source>Circulation</source><volume>123</volume><fpage>170</fpage><lpage>177</lpage><year>2011</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.945170</pub-id><pub-id pub-id-type="pmid">21200004</pub-id></element-citation></ref><ref id="b9-etm-0-0-5750"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>BT</given-names></name><name><surname>Iles</surname><given-names>TL</given-names></name><name><surname>Coles</surname><given-names>JA</given-names></name><name><surname>Sigg</surname><given-names>DC</given-names></name><name><surname>Iaizzo</surname><given-names>PA</given-names></name></person-group><chapter-title>Reversible and irreversible damage of the myocardium: Ischemia/reperfusion injury and cardioprotection</chapter-title><source>Handbook of Cardiac Anatomy, Physiology, and Devices</source><edition>3rd edition</edition><publisher-name>Springer International Publishing</publisher-name><publisher-loc>New York</publisher-loc><year>2015</year><pub-id pub-id-type="doi">10.1007/978-3-319-19464-6_42</pub-id></element-citation></ref><ref id="b10-etm-0-0-5750"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madamanchi</surname><given-names>C</given-names></name><name><surname>Alhosaini</surname><given-names>H</given-names></name><name><surname>Sumida</surname><given-names>A</given-names></name><name><surname>Runge</surname><given-names>MS</given-names></name></person-group><article-title>Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure</article-title><source>Int J Cardiol</source><volume>176</volume><fpage>611</fpage><lpage>617</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.08.007</pub-id><pub-id pub-id-type="pmid">25156856</pub-id></element-citation></ref><ref id="b11-etm-0-0-5750"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oremus</surname><given-names>M</given-names></name><name><surname>Don-Wauchope</surname><given-names>A</given-names></name><name><surname>McKelvie</surname><given-names>R</given-names></name><name><surname>Santaguida</surname><given-names>PL</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Balion</surname><given-names>C</given-names></name><name><surname>Booth</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Ali</surname><given-names>U</given-names></name><name><surname>Bustamam</surname><given-names>A</given-names></name><etal/></person-group><article-title>BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure</article-title><source>Heart Fail Rev</source><volume>19</volume><fpage>471</fpage><lpage>505</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s10741-014-9439-6</pub-id><pub-id pub-id-type="pmid">24986335</pub-id></element-citation></ref><ref id="b12-etm-0-0-5750"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boer</surname><given-names>BP</given-names></name><name><surname>Vieira</surname><given-names>ML</given-names></name><name><surname>Sampaio</surname><given-names>RO</given-names></name><name><surname>Abensur</surname><given-names>H</given-names></name><name><surname>Oliveira</surname><given-names>AG</given-names></name><name><surname>Fernandes</surname><given-names>JR</given-names></name><name><surname>Grinberg</surname><given-names>M</given-names></name></person-group><article-title>Correlation to NT-ProBNP and remodeling after cardiac surgery</article-title><source>Arq Bras Cardiol</source><volume>100</volume><fpage>469</fpage><lpage>475</lpage><year>2013</year><pub-id pub-id-type="pmid">23579620</pub-id></element-citation></ref><ref id="b13-etm-0-0-5750"><label>13</label><element-citation publication-type="journal"><collab collab-type="corp-author">Recombinant Human Brain Natriuretic Peptide Multicenter Clinical Study Group</collab><person-group person-group-type="author"><name><surname>Hu</surname><given-names>DY</given-names></name></person-group><article-title>Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: A multicenter, randomized, open label, controlled study</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><volume>39</volume><fpage>305</fpage><lpage>308</lpage><year>2011</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">21624304</pub-id></element-citation></ref><ref id="b14-etm-0-0-5750"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>G</given-names></name><name><surname>Miao</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI</article-title><source>Heart Vessels</source><volume>31</volume><fpage>490</fpage><lpage>498</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00380-015-0642-8</pub-id><pub-id pub-id-type="pmid">25637044</pub-id></element-citation></ref><ref id="b15-etm-0-0-5750"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: A systematic review and meta-analysis</article-title><source>Medicine (Baltimore)</source><volume>95</volume><fpage>e4757</fpage><year>2016</year><pub-id pub-id-type="doi">10.1097/MD.0000000000004757</pub-id><pub-id pub-id-type="pmid">27858837</pub-id></element-citation></ref><ref id="b16-etm-0-0-5750"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XQ</given-names></name><name><surname>Hong</surname><given-names>HS</given-names></name><name><surname>Lin</surname><given-names>XH</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name></person-group><article-title>Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide</article-title><source>Braz J Med Biol Res</source><volume>47</volume><fpage>646</fpage><lpage>654</lpage><year>2014</year><pub-id pub-id-type="doi">10.1590/1414-431X20143474</pub-id><pub-id pub-id-type="pmid">25014176</pub-id></element-citation></ref><ref id="b17-etm-0-0-5750"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats</article-title><source>Mol Med Rep</source><volume>7</volume><fpage>628</fpage><lpage>632</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/mmr.2012.1185</pub-id><pub-id pub-id-type="pmid">23165804</pub-id></element-citation></ref><ref id="b18-etm-0-0-5750"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkehaug</surname><given-names>JP</given-names></name><name><surname>Kildal</surname><given-names>AB</given-names></name><name><surname>Engstad</surname><given-names>ET</given-names></name><name><surname>Boardman</surname><given-names>N</given-names></name><name><surname>N&#x000e6;sheim</surname><given-names>T</given-names></name><name><surname>R&#x000f8;nning</surname><given-names>L</given-names></name><name><surname>Aasum</surname><given-names>E</given-names></name><name><surname>Larsen</surname><given-names>TS</given-names></name><name><surname>Myrmel</surname><given-names>T</given-names></name><name><surname>How</surname><given-names>OJ</given-names></name></person-group><article-title>Response to letter regarding article, &#x02018;Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity&#x02019;</article-title><source>Circ Heart Fail</source><volume>8</volume><fpage>1142</fpage><year>2015</year><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.115.002548</pub-id><pub-id pub-id-type="pmid">26738203</pub-id></element-citation></ref><ref id="b19-etm-0-0-5750"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>B</given-names></name></person-group><article-title>Natriuretic peptides as an adjunctive treatment for acute myocardial infarction: Insights from the meta-analysis of 1,389 patients from 20 trials</article-title><source>Int Heart J</source><volume>55</volume><fpage>8</fpage><lpage>16</lpage><year>2014</year><pub-id pub-id-type="doi">10.1536/ihj.13-109</pub-id><pub-id pub-id-type="pmid">24463927</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-etm-0-0-5750" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Cardiac output of two groups at different time points.</p></caption><graphic xlink:href="etm-15-03-2869-g00"/></fig><fig id="f2-etm-0-0-5750" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Pulmonary capillary wedge pressure (PAWP) of two groups at different time points.</p></caption><graphic xlink:href="etm-15-03-2869-g01"/></fig><fig id="f3-etm-0-0-5750" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Central venous pressure (CVP) of two groups at different time points.</p></caption><graphic xlink:href="etm-15-03-2869-g02"/></fig><table-wrap id="tI-etm-0-0-5750" orientation="portrait" position="float"><label>Table I.</label><caption><p>Baseline data of two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Item</th><th align="center" valign="bottom" rowspan="1" colspan="1">Observation group n=75</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control group n=75</th><th align="center" valign="bottom" rowspan="1" colspan="1">t/&#x003c7;<sup>2</sup></th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">30&#x02013;68</td><td align="center" valign="top" rowspan="1" colspan="1">30&#x02013;65</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">39/36</td><td align="center" valign="top" rowspan="1" colspan="1">34/41</td><td align="center" valign="top" rowspan="1" colspan="1">0.053</td><td align="center" valign="top" rowspan="1" colspan="1">0.513</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Average age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">43.56&#x000b1;6.42</td><td align="center" valign="top" rowspan="1" colspan="1">43.85&#x000b1;6.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.274</td><td align="center" valign="top" rowspan="1" colspan="1">0.784</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">22.13&#x000b1;3.45</td><td align="center" valign="top" rowspan="1" colspan="1">22.76&#x000b1;3.38</td><td align="center" valign="top" rowspan="1" colspan="1">1.130</td><td align="center" valign="top" rowspan="1" colspan="1">0.261</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Operation type (n, %)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.042</td><td align="center" valign="top" rowspan="1" colspan="1">0.874</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Valve repair or replacement</td><td align="center" valign="top" rowspan="1" colspan="1">29 (38.67)</td><td align="center" valign="top" rowspan="1" colspan="1">31 (41.33)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Correction of congenital heart disease</td><td align="center" valign="top" rowspan="1" colspan="1">19 (25.33)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (26.67)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Coronary artery and major blood vessel related surgery</td><td align="center" valign="top" rowspan="1" colspan="1">27 (36.00)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (32.00)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preoperative cardiac function (NYHA)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td align="center" valign="top" rowspan="1" colspan="1">0.739</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Grade II (n, %)</td><td align="center" valign="top" rowspan="1" colspan="1">32 (42.67)</td><td align="center" valign="top" rowspan="1" colspan="1">29 (38.67)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Grade III (n, %)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (57.33)</td><td align="center" valign="top" rowspan="1" colspan="1">46 (61.33)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tII-etm-0-0-5750" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of NT-proBNP levels in two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. of cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before operation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before medication after operation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Seven days after medication</th><th align="center" valign="bottom" rowspan="1" colspan="1">F-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">1315.35&#x000b1;221.14</td><td align="center" valign="top" rowspan="1" colspan="1">1934.06&#x000b1;321.13</td><td align="center" valign="top" rowspan="1" colspan="1">472.23&#x000b1;51.02</td><td align="center" valign="top" rowspan="1" colspan="1">76.312</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">1326.06&#x000b1;231.23</td><td align="center" valign="top" rowspan="1" colspan="1">1963.73&#x000b1;335.25</td><td align="center" valign="top" rowspan="1" colspan="1">1062.76&#x000b1;311.17</td><td align="center" valign="top" rowspan="1" colspan="1">75.431</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.290</td><td align="center" valign="top" rowspan="1" colspan="1">0.129</td><td align="center" valign="top" rowspan="1" colspan="1">16.219</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.772</td><td align="center" valign="top" rowspan="1" colspan="1">0.897</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tIII-etm-0-0-5750" orientation="portrait" position="float"><label>Table III.</label><caption><p>Comparison of changes of LVEF in two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. of cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before operation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Before medication after operation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Seven days after medication</th><th align="center" valign="bottom" rowspan="1" colspan="1">F-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">43.35&#x000b1;3.14</td><td align="center" valign="top" rowspan="1" colspan="1">50.06&#x000b1;3.13</td><td align="center" valign="top" rowspan="1" colspan="1">56.23&#x000b1;3.02</td><td align="center" valign="top" rowspan="1" colspan="1">9.432</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">43.06&#x000b1;3.23</td><td align="center" valign="top" rowspan="1" colspan="1">49.73&#x000b1;3.25</td><td align="center" valign="top" rowspan="1" colspan="1">51.76&#x000b1;3.17</td><td align="center" valign="top" rowspan="1" colspan="1">7.581</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.558</td><td align="center" valign="top" rowspan="1" colspan="1">0.633</td><td align="center" valign="top" rowspan="1" colspan="1">8.842</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">0.578</td><td align="center" valign="top" rowspan="1" colspan="1">0.527</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tIV-etm-0-0-5750" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Comparison of ventilator support and ICU indwelling time and postoperative complications of two groups of patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. of cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ventilator support time (h)</th><th align="center" valign="bottom" rowspan="1" colspan="1">ICU indwelling time (h)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Postoperative complication (n,%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">12.15&#x000b1;1.34</td><td align="center" valign="top" rowspan="1" colspan="1">26.16&#x000b1;3.33</td><td align="center" valign="top" rowspan="1" colspan="1">4 (5.33)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">16.76&#x000b1;1.53</td><td align="center" valign="top" rowspan="1" colspan="1">36.83&#x000b1;3.45</td><td align="center" valign="top" rowspan="1" colspan="1">13 (17.33)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td align="center" valign="top" rowspan="1" colspan="1">19.630</td><td align="center" valign="top" rowspan="1" colspan="1">19.271</td><td align="center" valign="top" rowspan="1" colspan="1">4.247</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.039</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tV-etm-0-0-5750" orientation="portrait" position="float"><label>Table V.</label><caption><p>Comparison of vital signs in two groups of patients during perioperative period.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No. of cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">SBP (mmHg)</th><th align="center" valign="bottom" rowspan="1" colspan="1">DBP (mmHg)</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR (beats/min)</th><th align="center" valign="bottom" rowspan="1" colspan="1">SaO2 (%)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Observation group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">115.35&#x000b1;3.14</td><td align="center" valign="top" rowspan="1" colspan="1">64.06&#x000b1;3.13</td><td align="center" valign="top" rowspan="1" colspan="1">90.06&#x000b1;8.17</td><td align="center" valign="top" rowspan="1" colspan="1">98.23&#x000b1;1.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">108.06&#x000b1;3.23</td><td align="center" valign="top" rowspan="1" colspan="1">59.73&#x000b1;3.25</td><td align="center" valign="top" rowspan="1" colspan="1">95.62&#x000b1;9.29</td><td align="center" valign="top" rowspan="1" colspan="1">94.76&#x000b1;1.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">t-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">14.015</td><td align="center" valign="top" rowspan="1" colspan="1">8.311</td><td align="center" valign="top" rowspan="1" colspan="1">3.899</td><td align="center" valign="top" rowspan="1" colspan="1">19.360</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap></floats-group></article>